36677-66-4

Upstream product

• 931-51-1 cyclohexylmagnesiumchloride 
• 5653-09-8 2-cyclohexyl-1-phenylethan-1-one 

Downstream Products

• 1069128-04-6 2-cyclohexyl-1-phenylnaphtho[2,1-b]thiophene 
• 5653-09-8 2-cyclohexyl-1-phenylethan-1-one 
• 1210067-29-0 C₁₅H₁₇NOS 
• 1427549-99-2 ethyl 3-cyclohexyl-1-methyl-2-phenyl-1H-imidazo[1,2-b]pyrazole-7-carboxylate 
• 1427550-00-2 3-cyclohexyl-1-methyl-2-phenyl-1H-imidazo[1,2-b]pyrazole-7-carboxylic acid 
• 1427549-63-0 ethyl (2E)-3-(4-{[(1-{[(3-cyclohexyl-1-methyl-2-phenyl-1H-imidazo[1,2-b]pyrazole-7-yl)carbonyl]amino}cyclobutyl)carbonyl]amino}phenyl)prop-2-enoate 
• 1427549-65-2 (2E)-3-(4-{[(1-{[(3-cyclohexyl-1-methyl-2-phenyl-1H-imidazo[1,2-b]pyrazole-7-yl)carbonyl]amino}cyclobutyl)carbonyl]amino}phenyl)prop-2-enoic acid 

Relevant academic research and scientific papers

Structural Modification of the Designer Stimulant α-Pyrrolidinovalerophenone (α-PVP) Influences Potency at Dopamine Transporters

α-Pyrrolidinovalerophenone (α-PVP, 7) is an illegal synthetic stimulant that is being sold on the clandestine market as flakka and gravel. The potent pharmacological effects of α-PVP are presumably mediated by inhibition of dopamine uptake at the dopamine transporter (DAT). However, little is known about how structural modification of α-PVP influences activity at DAT. Eleven analogs of α-PVP were synthesized and examined for their ability to inhibit uptake of [3H]dopamine and [3H]serotonin in rat brain synaptosomes. None of the analogs significantly inhibited [3H]serotonin uptake when tested at 10 μM at the serotonin transporter (SERT). All of the analogs behaved as DAT reuptake inhibitors, but potencies varied over a >1500-fold range. Potency was primarily associated with the nature of the α-substituent, with the more bulky substituents imparting the highest potency. Expansion of the pyrrolidine ring to a piperidine reduced potency up to 10-fold, whereas conformational constraint in the form of an aminotetralone resulted in the least potent compound. Our study provides the first systematic and comparative structure-activity investigation on the ability of α-PVP analogs to act as inhibitors of DAT.

COMPOUNDS FOR THE TREATMENT OF HCV

The present invention relates to viral polymerase inhibitors of formula (I), salts, solvates, hydrates, racemates, enatiomers and isomers thereof, in particular inhibitors of viral polymerases within the Flaviviridae family such as hepatitis C virus (HCV), processes for their preparation and their use in the treatment of Flaviviridae viral infection such as Hepatitis C virus (HCV) infections